Acromegaly, Cardiomyopathies
Conditions
Brief summary
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient medicine is available for acromegalic cardiomyopathy until now and there were limited studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients and independent of blood glucose control. We planed to evaluate the structure of heart by MRI before and after 6 months treatment with empagliflozin in acromegalic patients to investigate the effect of empagliflozin on acromegalic cardiomyopathy.
Interventions
DRUGEmpagliflozin
empagliflozin of 10mg/day is added on the basis of primary care
Sponsors
Huashan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* patients with pituitary GH adenomas confirmed by surgery active acromegalic patients although treated with surgery,radiation therapy and somatostatin analogs
Exclusion criteria
* patients with contraindications to empagliflozin pregnant patients patients with poor control of hypertension(SBP\>150mmHg or DBP\>95mmHg patients with contraindications to MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular mass index | 6 months | the changes in left ventricular mass index by heart MRI |
Countries
China
Contacts
Primary ContactCuiyun Wu
Outcome results
None listed